Two Democratic senators are questioning whether Trump lawyer Rudy Giuliani’s past representation of an opioid manufacturer led the company to receive lenient treatment from the federal government.

Sens. Maggie Hassan Margaret (Maggie) HassanDemocrats step up hardball tactics as Supreme Court fight heats up Congress needs to prioritize government digital service delivery Senate Democrats demand answers on migrant child trafficking during pandemic MORE (D-N.H.) and Sheldon Whitehouse Sheldon WhitehouseThe Hill's Morning Report - Sponsored by Facebook - Trump previews SCOTUS nominee as 'totally brilliant' Feinstein 'surprised and taken aback' by suggestion she's not up for Supreme Court fight Hillicon Valley: Murky TikTok deal raises questions about China's role | Twitter investigating automated image previews over apparent algorithmic bias | House approves bill making hacking federal voting systems a crime MORE (D-R.I.) sent separate letters to the Department of Justice (DOJ) and the Drug Enforcement Agency (DEA) this week asking whether Giuliani’s work years ago on behalf of both agencies while he was representing Purdue Pharma may have led to unduly lenient treatment for the company.

Giuliani, the former mayor of New York who joined President Trump Donald John TrumpSteele Dossier sub-source was subject of FBI counterintelligence probe Pelosi slams Trump executive order on pre-existing conditions: It 'isn't worth the paper it's signed on' Trump 'no longer angry' at Romney because of Supreme Court stance MORE’s personal legal team in April to lead the response to special counsel Robert Mueller Robert (Bob) MuellerCNN's Toobin warns McCabe is in 'perilous condition' with emboldened Trump CNN anchor rips Trump over Stone while evoking Clinton-Lynch tarmac meeting The Hill's 12:30 Report: New Hampshire fallout MORE's investigation into potential collusion between the Trump campaign and Russia in its election interference efforts, was hired by Purdue in 2002 and represented the company in the mid-2000s.

ADVERTISEMENT

Purdue manufactures OxyContin, and the company has come under fire for its alleged deceptive and fraudulent marketing of the drug. The company is accused of intentionally misleading the public by hiding the drug’s potential for abuse.

Purdue is currently facing dozens of lawsuits for the role OxyContin has allegedly played in America's opioid epidemic.

In the letters, the senators cite reports that Giuliani represented Purdue in negotiations with the DOJ over the fraudulent marketing schemes.

At the same time, Giuliani’s firm was reportedly part of a $1 million consulting contract with the DOJ to provide advice on reorganizing its major drug investigations and Giuliani was also personally raising money for a DEA museum.

Ultimately, political appointees at the DOJ accepted a plea from Purdue that it “misbranded” OxyContin, and the company paid a $640 million fine in 2007.

Giuliani also participated in meetings with DEA officials and helped broker a deal where Perdue paid a $2 million fine for record-keeping violations but admitted no wrongdoing, the senators said.

“These facts suggest [DOJ and] DEA officials may have agreed to an inappropriately lenient treatment of Purdue Pharma simply because it was represented by Mr. Giuliani,” the senators wrote in the letters.

“The public health consequences of that decision may have been immense, and deserve greater scrutiny by Congress, [DOJ], and DEA,” the lawmakers added.

The Senators asked for DEA and DOJ to respond by Sept. 21.